TRIP13 modulates protein deubiquitination and accelerates tumor

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

Biomolecules, Free Full-Text

Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma

Journal of Cellular Physiology, Cell Biology Journal

Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway

AAA ATPase protein–protein interactions as therapeutic targets in cancer - ScienceDirect

Deubiquitinating Enzyme: Most Up-to-Date Encyclopedia, News & Reviews

Frontiers Regulation of Glucose, Fatty Acid and Amino Acid Metabolism by Ubiquitination and SUMOylation for Cancer Progression

Current and future directions of USP7 interactome in cancer study - ScienceDirect

TRIP13 knockdown induced CLL cells apoptosis. (A) and (B) Activated

Journal of Cellular Physiology, Cell Biology Journal

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma - ScienceDirect

Frontiers USP13: Multiple Functions and Target Inhibition

C-MYC up-regulated TRIP13 transactivity. Dual-luciferase reporter assay

Nek2 overexpression causes HeLa cells to become resistant to